| Year |
Citation |
Score |
| 2023 |
Blose BA, Lai A, Crosta C, Thompson JL, Silverstein SM. Retinal Neurodegeneration as a Potential Biomarker of Accelerated Aging in Schizophrenia Spectrum Disorders. Schizophrenia Bulletin. PMID 37459382 DOI: 10.1093/schbul/sbad102 |
0.343 |
|
| 2019 |
Demmin DL, Mote J, Beaudette DM, Thompson JL, Silverstein SM. Retinal functioning and reward processing in schizophrenia. Schizophrenia Research. PMID 31280976 DOI: 10.1016/J.Schres.2019.06.019 |
0.335 |
|
| 2015 |
Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D'Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. Jama Psychiatry. 72: 316-24. PMID 25651194 DOI: 10.1001/Jamapsychiatry.2014.2414 |
0.302 |
|
| 2013 |
Poels EM, Girgis RR, Thompson JL, Slifstein M, Abi-Dargham A. In vivo binding of the dopamine-1 receptor PET tracers [¹¹C]NNC112 and [¹¹C]SCH23390: a comparison study in individuals with schizophrenia. Psychopharmacology. 228: 167-74. PMID 23460265 DOI: 10.1007/s00213-013-3026-8 |
0.33 |
|
| 2013 |
Thompson JL, Urban N, Slifstein M, Xu X, Kegeles LS, Girgis RR, Beckerman Y, Harkavy-Friedman JM, Gil R, Abi-Dargham A. Striatal dopamine release in schizophrenia comorbid with substance dependence Molecular Psychiatry. 18: 909-915. PMID 22869037 DOI: 10.1038/mp.2012.109 |
0.352 |
|
| 2013 |
Thompson JL, Urban N, Slifstein M, Xu X, Kegeles LS, Girgis RR, Beckerman Y, Harkavy-Friedman JM, Gil R, Abi-Dargham A. Striatal Dopamine Release in Schizophrenia Comorbis with Substance Dependence Catecholamine Research in the 21st Century: Abstracts and Graphical Abstracts, 10th International Catecholamine Symposium, 2012. 152-153. DOI: 10.1016/B978-0-12-800044-1.00135-5 |
0.338 |
|
| 2012 |
Abi-Dargham A, Xu X, Thompson JL, Gil R, Kegeles LS, Urban N, Narendran R, Hwang DR, Laruelle M, Slifstein M. Increased prefrontal cortical D1 receptors in drug naïve patients with schizophrenia: A PET study with [11C]NNC112 Journal of Psychopharmacology. 26: 794-805. PMID 21768159 DOI: 10.1177/0269881111409265 |
0.329 |
|
| 2011 |
Miyake N, Thompson J, Skinbjerg M, Abi-Dargham A. Presynaptic dopamine in schizophrenia. Cns Neuroscience & Therapeutics. 17: 104-9. PMID 21199451 DOI: 10.1111/j.1755-5949.2010.00230.x |
0.381 |
|
| 2009 |
Thompson JL, Urban N, Abi-Dargham A. How have developments in molecular imaging techniques furthered schizophrenia research? Imaging in Medicine. 1: 135-153. PMID 21243081 DOI: 10.2217/IIM.09.22 |
0.309 |
|
| 2005 |
Thompson JL, Watson JR, Steinhauer SR, Goldstein G, Pogue-Geile MF. Indicators of genetic liability to schizophrenia: a sibling study of neuropsychological performance. Schizophrenia Bulletin. 31: 85-96. PMID 15888428 DOI: 10.1093/Schbul/Sbi009 |
0.477 |
|
| 2004 |
Thompson JL, Pogue-Geile MF, Grace AA. Developmental pathology, dopamine, and stress: a model for the age of onset of schizophrenia symptoms. Schizophrenia Bulletin. 30: 875-900. PMID 15954196 DOI: 10.1093/Oxfordjournals.Schbul.A007139 |
0.475 |
|
| 2003 |
POGUEGEILE M, CHOWDARI K, WOOD J, THOMPSON J, NIMGAONKAR V. Heterogeneity of schizophrenia: A genetic association study of variation in cognitive function and chromosome 13 markers Schizophrenia Research. 60: 89-89. DOI: 10.1016/S0920-9964(03)80651-5 |
0.432 |
|
| Show low-probability matches. |